TEXO Ventures

Jerry DeVries, a Managing Partner and co-founder, drives investment decisions alongside Principal Philip Edmondson-Jones. DeVries brought a McKinsey and startup-operating background to the founding thesis, and the partnership remains deliberately small — concentrated generalist decision-making in a healthcare-focused firm, which is atypical relative to the specialist MD-MBA partnership model common in health-tech venture.

TEXO leans heavily on relationships within Texas's large healthcare-provider systems, including Baylor Scott & White, Ascension Seton, and the University of Texas medical network. The firm identifies founders whose technology requires clinical validation, then uses local provider access as both a diligence tool and a value-add for portfolio companies. A portion of pipeline also arrives through Austin's angel networks and regional accelerators.

No. TEXO has exclusively invested in healthcare since its 2013 launch, spanning digital health, healthcare services, insurance technology, and enterprise software that serves providers and payers. The firm does not pursue consumer internet, clean energy, or non-health enterprise deals, and it has maintained this sector focus across multiple fund vintages per SEC filings.

TEXO targets pre-seed and seed stages, occasionally participating in Series A rounds. The firm prefers to lead or co-lead rounds where it can secure meaningful ownership at entry and maintain pro-rata rights into later financings. Check sizes are consistent with early-stage health-tech venture, though exact figures have not been publicly disclosed.

TEXO is a traditional venture capital firm that raises institutional and high-net-worth capital through limited partner fund structures. It is not a single-family office, though its Austin-based, sub-$100 million fund model shares some characteristics with family-office direct-investment programs in terms of discretion and hold periods.

TEXO was founded with a Texas-centric view of healthcare venture, arguing that Austin, Houston, and Dallas are undercapitalized relative to the clinical assets concentrated there. While the firm will invest nationally when a founding team can stage pilots or secure customers in Texas, its core origination and value-creation model depends on Texas-based clinical partners. This is a binding constraint on deal selection, not an aspirational preference.

No. TEXO has not publicly disclosed total AUM across its funds. Public SEC filings confirm three fund vintages (2013, 2016, 2019) with targets in the $20–$50 million range each, but aggregate deployment and current assets remain undisclosed. The firm maintains a deliberately low public profile on fundraising metrics.